GRAI-MATTER-LABS
4.10.2021 13:04:09 CEST | Business Wire | Press release
GrAI Matter Labs (GML), a pioneer of brain-inspired ultra-low latency computing solutions, and FRAMOS, a leading global imaging provider, will unite at VISION 2021 to create Life-Ready AI for Industrial Vision Platforms. This project is based on FRAMOS’s D435e Industrial Depth Camera and GML's GrAI VIP (Vision Inference Processor) and was formed to advance vision application development in robotics, automation, IoT-connected manufacturing, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005462/en/
The Life-Ready AI for Industrial Vision Platforms will be built on GML's pioneering development of brain-inspired computing techniques for enhanced efficiencies that leverages FRAMOS’s state of the art stereo depth sensing technology for industrial environments through their D435e stereo depth camera. The platform offers full bodied IP66 rated cameras, or board level modules for easy and flexible integration into industrial designs, both with M12 ethernet and M8 power connectors, and are enabled with ultra low latency AI processing for applications such as orientation and tracking for robots; navigation of autonomous transport systems (AGVs); among some of the many possibilities.
GML and FRAMOS will showcase the integration of the Life-Ready AI platform and D435e Industrial Depth Camera at the Vision 2021 in Stuttgart, Germany, taking place over three days starting October 5th .
“We are proud to be working with FRAMOS to couple GML's "Life-Ready AI" chips, state-of-the-art brain-inspired computing architecture, and FRAMOS' robust D400e depth camera series, to enable many types of new low latency applications in industrial manufacturing that will allow us to bring AI processing closer to where data is generated. This collaboration enables us to realize the full potential of end-point AI, allowing for actionable insights into manufacturing operations to improve productivity and lower costs,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Ferdinand Reitze, FRAMOS Product Manager 3D, is delighted about the integration, saying: “GML successfully reduced the footprint of AI inference at the edge, while achieving best results, speed and low latency. Together with our D400e series, the Life-Ready AI chips will enable new ways to resolve todays and tomorrows challenges in robotics and automation for our customers.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About FRAMOS
FRAMOS® is an imaging expert, trusted advisor, and vision solutions provider. Since 1981 FRAMOS implements the best current and emerging imaging technologies for specific customer requirements and applications. FRAMOS meets these requirements with advanced and proven imaging components from a global network of renowned partners, and proprietary IP.
More than 170 FRAMOS employees world-wide are passionate about the unlimited potential of imaging and help customers achieve the optimum results from every possible scenario. FRAMOS drives and ensures the entire product development journey. This journey starts with the careful selection of imaging components, like image sensors, lenses, through various 3D technologies, to custom development tailored to individual needs and time frames. FRAMOS listens and understands customer challenges. With innovative solutions FRAMOS ensures successful project outcomes and develops long-term customer relations.
For more information, please visit www.framos.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom